# Mirai Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirai-bio

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.miraibio.com
- Total disclosed funding: $50M
- Latest round: Series A (Sep 26, 2024)
- Investors on record: 1

## About

Based in the US, Mirai Bio provides an innovative platform that enhances the delivery of genetic medicines through advanced machine learning techniques and lipid formulations.Mirai Bio specializes in optimizing genetic medicine delivery systems. Founded by Hari Pujar, the company is headquartered in Cambridge, US. On September 26, 2024, Mirai Bio raised USD 50 mn in Series A funding from Flagship Pioneering, bringing the total amount raised to USD 50 mn and a current company valuation of USD 179.85 mn.Mirai offers a platform designed to optimize the delivery of genetic medicines by leveraging machine learning and innovative lipid formulations. Their services include generative design that creates potent and targeted cargo for therapeutic agents, effectively reaching diverse tissues and cell types. The platform addresses limitations of current delivery systems, significantly advancing genome engineering, tRNA, mRNA, and DNA therapeutics. Their clientele consists of biotech firms and pharmaceutical companies in North America and Europe that utilize Mirai's technology to accelerate the development of genetic therapies from concept to clinical application.Mirai generates revenue through strategic partnerships with biotech companies, using a business-to-business (B2B) model. Revenue is derived from project-based fees, milestone payments, and potential royalties from successful commercialization of therapies developed through these collaborations. Their offerings, centered around machine-learning optimized delivery vehicles, are vital for maximizing therapeutic efficacy while facilitating market entry. Pricing and transaction structures are customized to meet the specific needs of each partnership.In September 2024, Mirai Bio raised USD 50 mn in Series A funding to advance its platform and accelerate genetic medicine development across various therapeutic areas. The funding will support the design and launch of new products aimed at expanding their reach into additional therapeutic domains. The company plans to explore new markets, particularly in Europe and Asia, with a focus on establishing partnerships by the end of 2025.

## Funding rounds

- Series A, Sep 26, 2024, $50M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A